ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

AstraZeneca’s resurgent cancer division could have another winner on its hands. Stellar data with newly-approved BTK inhibitor Calquence suggests it could be a major challenger to class leader Imbruvica from Johnson & Johnson/AbbVie.